Drug Trial Radar · NCT07745725
A Phase II Study of TollB-001 Tablets in Systemic Sclerosis
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Oct 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- Toll Biotech Co. Ltd. (Beijing)Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase II study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of TollB-001 Tablets in adults aged 18 to 70 years (male or female) with systemic sclerosis (SSc).
Conditions
- Systemic Sclerosis (SSc)
Interventions
TollB-001 TabletDrug
TollB-001 Tablets
PlaceboDrug
Placebo Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rodnan Skin Score (mRSS)Time frame: up to 12 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Toll Biotech, 2108-B007, No. 9 West Beisihuan Road, Haidian District, Beijing, People's Republic of China
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.